All Stories

  1. Killing Monkeypox Virus in Blood Products
  2. Preservation of neutralizing antibody function in COVID‐19 convalescent plasma treated using a riboflavin and ultraviolet light‐based pathogen reduction technology
  3. A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model
  4. Releasates of riboflavin/UV‐treated platelets: Microvesicles suppress cytokine‐mediated endothelial cell migration/proliferation
  5. Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology
  6. Pilot Acute Safety Evaluation of Innocell™ Cancer Immunotherapy in Canine Subjects
  7. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light
  8. A novel cancer immunotherapy utilizing autologous tumour tissue
  9. Pathogen Reduction of SARS-CoV-2 Virus in Plasma and Whole Blood using Riboflavin and UV Light
  10. Ignorance is not bliss
  11. Pathogen reduction of whole blood: utility and feasibility
  12. Efficiency of riboflavin and ultraviolet light treatment against high levels of biofilm-derivedStaphylococcus epidermidisin buffy coat platelet concentrates
  13. Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage
  14. Photochemical eradication of methicillin-resistantStaphylococcus aureusby blue light activation of riboflavin
  15. Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood
  16. Characterization of posttransfusionPlasmodium falciparuminfection in semi‐immune nonparasitemic patients
  17. Protein translation occurs in platelet concentrates despite riboflavin/UV light pathogen inactivation treatment
  18. Riboflavin and ultraviolet light: impact on dengue virus infectivity
  19. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial
  20. Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets
  21. Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro
  22. Riboflavin-ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells
  23. Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
  24. Treatment of Whole Blood With Riboflavin and UV Light
  25. Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment
  26. Large animal evaluation of riboflavin and ultraviolet light-treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model
  27. The effect of riboflavin and ultraviolet light on the infectivity of arboviruses
  28. Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method
  29. Reduction ofLeishmania donovaniinfectivity in whole blood using riboflavin and ultraviolet light
  30. Chemical and Biological Mechanisms of Pathogen Reduction Technologies
  31. Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light
  32. Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment – A comparative study
  33. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment
  34. Immune modulation and lack of alloimmunization following transfusion with pathogen‐reduced platelets in mice
  35. Inactivation ofPlasmodiumspp. in plasma and platelet concentrates using riboflavin and ultraviolet light
  36. Development of a riboflavin and ultraviolet light-based device to treat whole blood
  37. Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time
  38. A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia
  39. In Reply to: “Is the SCID mouse model applicable to human acute lung injury?”
  40. Fresh Whole Blood Use for Hemorrhagic Shock
  41. Riboflavin and ultraviolet light reduce the infectivity ofBabesia microtiin whole blood
  42. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system
  43. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease?
  44. Preparation of cryoprecipitate from riboflavin and UV light-treated plasma
  45. Quality of proteins in riboflavin and UV light-treated FFP during 1year of storage at −18°C
  46. In response to Morrison-McKell and wehrli
  47. Improving blood safety and patient outcomes with pathogen reduction technology
  48. In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days
  49. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood
  50. Establishment of the first International Repository for Transfusion-Relevant Bacteria Reference Strains: ISBT Working Party Transfusion-Transmitted Infectious Diseases (WP-TTID), Subgroup on Bacteria
  51. In reply
  52. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover
  53. FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety
  54. Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2years at −30°C
  55. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood
  56. Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light
  57. Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions
  58. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology
  59. White blood cell inactivation after treatment with riboflavin and ultraviolet light
  60. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function
  61. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology
  62. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology
  63. Defining “adequate” pathogen reduction performance for transfused blood components
  64. Errata
  65. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at −30°C
  66. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products
  67. Evaluation of the Mirasol platelet reduction technology system against Babesia microti in apheresis platelets and plasma
  68. Pathogen reduction technology (Mirasol®) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS
  69. BLOOD COMPONENTS: Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates
  70. IMMUNOHEMATOLOGY: Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment
  71. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns
  72. Evaluation of Different Preparation Procedures of Pathogen Reduction Technology(Mirasol®)-Treated Platelets Collected by Plateletpheresis
  73. Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons
  74. Reduction of prion infectivity in packed red blood cells
  75. Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation
  76. Treatment With Riboflavin and Ultraviolet Light Prevents Alloimmunization to Platelet Transfusions and Cardiac Transplants
  77. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light
  78. Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model
  79. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2?/??c?/?double knockout mice
  80. The Mirasol™ PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends
  81. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects
  82. Functional inactivation of white blood cells by Mirasol treatment
  83. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light
  84. Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage
  85. Comparison of computerized formulae for determination of platelet recovery and survival
  86. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction
  87. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates
  88. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology
  89. An Action Spectrum of the Riboflavin-photosensitized Inactivation of Lambda Phage¶
  90. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products
  91. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light
  92. Riboflavin and UV-Light Based Pathogen Reduction: Extent and Consequence of DNA Damage at the Molecular Level
  93. The design and development of selective, photoactivated drugs for sterilization of blood products
  94. Photochemical and Photophysical Studies of 3‐Amino‐6‐lodoacridine and the Inactivation of λ Phage
  95. Measurement of Transmitted Light as an Indicator of Cryopreserved Platelet Viability
  96. Survival of lyophilized and reconstituted human red blood cells in vivo
  97. Selective inactivation of viruses in the presence of human platelets: UV sensitization with psoralen derivatives.
  98. DRAMATIC IMPROVEMENTS IN VIRAL INACTIVATION WITH BROMINATED PSORALENS, NAPHTHALENES AND ANTHRACENES
  99. Refrigerated storage of lyophilized and rehydrated, lyophilized human red cells
  100. Preservation of metabolic activity in lyophilized human erythrocytes.
  101. EPR spectroscopy of triplet aryl nitrenes covalently bound to .alpha.-chymotrypsin. Application of low-temperature methods to photoaffinity labeling
  102. Spectroscopy Of Nitrenes Bound To ∝-Chymotrypsin